Jean-Claude Muller
Feedback from the J.P. Morgan Conference
The 44th Annual J.P. Morgan Healthcare Conference took place from January 12-15, 2026, in San Francisco.
Although we have not been present physically in San Francisco, we have been able to connect into several panel discussions and get access to some presentations. Of course, what is missing is the
Rapport de Prévision Mondiale 2026
En début de chaque mois de janvier, des instituts et organismes publics ou privés publient des rapports plus ou moins complets sur les prévisions de l’année. Une partie de ces données est relayée par les médias et puis elles sont généralement oubliées sauf par des économistes, des investisseurs, des
2025: A turbulent year for the biotechnology industry
CEOS of biotech companies and financial investors assess the year 2025 with a different viewpoint.
US FDA Novel Drug Approval for 2025
SPECIAL REPORT 25.18
We wish all our readers and followers a Happy and Prosperous Year 2026
US FDA Novel Drug Approval for 2025
Despite a major turmoil and an important number of resignations, the U.S FDA’s Center for Drug Evaluation and Research (CDER) indicates that the health
Welcome to jcmuller.com
Over the last twelve years, through the btobioinnovation platform, we have published around 400 news and special reports and thus developed a strong and reliable network of readers and followers.
We sincerely thank you for the trust you have placed into our former publications, and we look forward to continuing
Update on Alzheimer’s disease treatments
2025 brings disappointing news for Alzheimer's patients in Europe: regulatory hurdles for new treatments and major clinical trial failures.